What Is Echinomycin? Definition and What Research Reports

Echinomycin — also written quinomycin A — is a small, rigid cyclic depsipeptide natural product produced by Streptomyces bacteria, assembled by nonribosomal peptide synthetase (NRPS) machinery rather than by ribosomal translation, as summarised in a review of echinomycin biosynthesis (PMID 23856054). Its defining structural feature is a pair of quinoxaline-2-carboxylic acid chromophores attached to a cross-bridged peptide ring, which allows the molecule to insert into double-stranded DNA at two sites at once — the property that gives it the label bisintercalator. In the research literature the name is used to refer to this specific quinomycin-family compound and, increasingly, to a family of semi-synthetic analogues built on the same scaffold (PMID 38561454).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or an investigational compound. Echinomycin is a laboratory research substance, not an approved medicine, and nothing below describes how it is or should be used by any person.

What class of molecule is it?

Echinomycin sits at the boundary of several vocabularies, which is why it appears in peptide glossaries at all. It is peptidic in origin — its ring is made of amino acid and hydroxy-acid units linked by amide and ester bonds — but it is not a linear, ribosomally produced peptide of the kind most peptide references describe. The biosynthesis review classified echinomycin among the quinoxaline antibiotics and described the NRPS-based enzymology that builds the depsipeptide ring and installs the quinoxaline chromophores (PMID 23856054).

How the term is used in research

Three distinct usages of "echinomycin" recur in the literature, and they are worth separating because they belong to different fields.

• As a natural-product chemistry term. Here echinomycin names the parent quinomycin scaffold whose biosynthetic gene cluster and NRPS logic have been dissected, work that the 2013 review framed as a template for engineering related quinoxaline compounds (PMID 23856054).
• As a molecular-biology tool. Researchers use it as a reference inhibitor of hypoxia-inducible factor-1 (HIF-1), because it interferes with the transcription factor's interaction with DNA rather than with its synthesis (PMID 28183349).
• As a microbiology probe. Because it is an antibiotic made by bacteria, echinomycin is used to study how producing and non-producing organisms defend themselves against DNA-binding drugs, as in studies of the resistance protein Ecm16 (PMID 37198233).

What the published literature reports

HIF-1 inhibition and downstream models

The most frequently cited property of echinomycin in modern papers is transcriptional inhibition of HIF-1. An experimental eye research paper reported that echinomycin mitigated ocular angiogenesis through transcriptional inhibition of hypoxia-inducible factor-1 (PMID 33639134). In transplantation immunology, a translational medicine study described echinomycin as a HIF-1α inhibitor and reported that it reduced acute graft-versus-host disease while preserving the graft-versus-leukemia effect in the models examined (PMID 28183349). A separate group in hematology and oncology reported echinomycin as a candidate agent against Kaposi's sarcoma herpesvirus (KSHV)-related malignancies (PMID 37143124). These were laboratory and animal investigations; none of them established an approved clinical use, and the cited abstracts do not support any statement about human treatment.

Antibacterial activity and resistance biology

Echinomycin also appears in antimicrobial research. A 2024 mLife study reported that the arabinosyltransferase-related proteins EmbB and EmbC regulate the sensitivity of Mycobacterium abscessus to echinomycin (PMID 39359678). On the producer side, researchers characterised Ecm16, a UvrA-like protein that confers echinomycin resistance, and the study reported that Ecm16 requires ATPase activity to render that resistance (PMID 35534931). A follow-on structural paper described structural and functional analyses of the echinomycin resistance-conferring protein Ecm16 from Streptomyces lasalocidi (PMID 37198233). Together these reports frame echinomycin less as a drug candidate and more as a probe for DNA-damage-response and self-resistance mechanisms in bacteria.

Analogue chemistry

Because the parent molecule is potent but chemically demanding, several groups have made derivatives. A 2024 Scientific Reports paper described the synthesis and biological evaluation of echinomycin analogues as potential colon cancer agents (PMID 38561454). This line of work is the reason "echinomycin analogue" and "quinomycin derivative" turn up alongside the parent term in chemistry indexes.

A note on retracted literature

Anyone reading around this term will encounter a retraction. A 2020 Cancers article on actively targeted nanodelivery of echinomycin in chemoresistant pancreatic cancer was subsequently retracted, with the retraction notice published in 2025 (PMID 41347777). Retracted findings should not be treated as evidence, and they are noted here only so readers recognise the record if they meet it in a citation list. Checking retraction status is part of reading any preclinical literature.

Safety and Tolerability: What Studies Report

The verified papers summarised on this page are mechanistic, chemical and animal-model reports rather than human safety trials, and their abstracts do not characterise an adverse-event profile in people. What they do imply is a general caution shared by all DNA-binding agents: a molecule that intercalates into double-stranded DNA is not selective for a single cell type by design, which is one reason the analogue and targeted-delivery work exists in the first place (PMID 38561454). Resistance studies reinforce the same point from the microbial side, since organisms that encounter echinomycin require dedicated proteins such as Ecm16 to survive it (PMID 35534931). Readers should not infer tolerability in humans from preclinical models, and this entry describes no dose, schedule or route for any person.

Where echinomycin fits among peptides

Echinomycin is a useful edge case for anyone learning peptide vocabulary. Most entries in a peptide glossary describe linear chains of proteinogenic amino acids made by ribosomes and acting at cell-surface receptors. Echinomycin is peptide-derived but cyclic, depsipeptidic, enzymatically assembled by NRPS modules, and it acts on DNA itself rather than on a receptor (PMID 23856054). Because of that, findings about echinomycin do not generalise to therapeutic peptides, and vice versa.

Terms often seen alongside it

• Quinomycin A — a direct synonym for echinomycin.
• Bisintercalator — a molecule binding DNA at two intercalation sites (PMID 23856054).
• HIF-1α — the transcription factor subunit targeted in the studies described above (PMID 28183349).
• Ecm16 — a UvrA-like resistance protein studied in echinomycin producers (PMID 37198233).
• NRPS — nonribosomal peptide synthetase, the enzyme class that builds it (PMID 23856054).

Summary of the evidence base

In short: echinomycin is a bacterial quinoxaline depsipeptide antibiotic that binds DNA by bisintercalation (PMID 23856054), is used experimentally as a HIF-1 transcriptional inhibitor (PMID 33639134), and has been examined in preclinical models of graft-versus-host disease (PMID 28183349), KSHV-associated malignancy (PMID 37143124) and mycobacterial infection (PMID 39359678). The literature is preclinical, one prominent delivery paper has been retracted (PMID 41347777), and this entry is definitional reference material only, not guidance of any kind.

References

• Echinomycin biosynthesis (Current Opinion in Chemical Biology, 2013)
• HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect (Journal of Translational Medicine, 2017)
• Echinomycin mitigates ocular angiogenesis by transcriptional inhibition of the hypoxia-inducible factor-1 (Experimental Eye Research, 2021)
• The UvrA-like protein Ecm16 requires ATPase activity to render resistance against echinomycin (Molecular Microbiology, 2022)
• Echinomycin as a promising therapeutic agent against KSHV-related malignancies (Journal of Hematology & Oncology, 2023)
• Structural and functional analyses of the echinomycin resistance conferring protein Ecm16 from Streptomyces lasalocidi (Scientific Reports, 2023)
• Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent (Scientific Reports, 2024)
• EmbB and EmbC regulate the sensitivity of Mycobacterium abscessus to echinomycin (mLife, 2024)
• RETRACTED: Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo (Cancers, 2025 retraction notice)